Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian Patients

Journal of Medical Virology

Volumn 87, Issue 3, 2015, Pages 428-440

  Abd El Wahab, Ekram W ^a   Mikheal, Ashraf ^a,b   Sidkey, Fathallah ^c   Shatat, Hanan Z ^a  

^a High Institute of Public Health Egypt   (Egypt)

^b Ministry of Health and Population   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Antiviral combination therapy; Hepatitis C; Insulin resistance

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; GLUCOSE; INSULIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTHROMBIN; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; AGING; ANTIVIRAL THERAPY; ARTICLE; ASSESSMENT OF HUMANS; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BODY MASS; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; EGYPTIAN; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEPATITIS C; HOMEOSTATIC MODEL ASESSMENT INSULIN RESISTANCE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD; ADOLESCENT; COMPLICATION; EGYPT; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

HEPATITIS C VIRUS;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; EGYPT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84921328196     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24092     Document Type: Article

References (60)

1. Aghemo A, Rumi MG, Colombo M. 2009. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther 7:925-935.
2. Alan F. HCV treatment: Predictors of treatment response. hscpFACTsheet (7) Hepatitis C Support Project Available at wwwhcvadvocateorg.
3. Badar S, Khubaib B, Idrees M, Hussain A, Awan Z, Butt S, Afzal S, Akram M, Fatima Z, Aftab M, Saleem S, Munir S, Rauff B, Naudhani M, Ali L, Ali M, Rehman I. 2012. Association of hepatitis C virus with insulin resistance: Evidences from animal studies and clinical studies. Hepat Mon 12:11-15.
4. Banerjee D, Williams EV, Ilott J, Monypenny IJ, Webster DJ. 2001. Obesity predisposes to increased drainage following axillary node clearance: A prospective audit. Ann R Coll Surg Engl 83:268-271.
5. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. 2003. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600-609.
6. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. 2000. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-63.
7. Bostan N, Mahmood T. 2010. An overview about hepatitis C: A devastating virus. Crit Rev Microbiol 36:91-133.
8. Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M. 2012. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care 35:1090-1094.
9. Bugianesi E, Salamone F, Negro F. 2012. The interaction of metabolic factors with HCV infection: Does it matter. J Hepatol 56:S56-S65.
10. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Ceron D, Degott C, Cacoub P, Perronne C. 2004. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV- infected patients: A randomized controlled trial. JAMA 292:2839-2848.
11. D'Souza R, Sabin CA, Foster GR. 2005. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100:1509-1515.
12. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Wang LY, Chang WY, Chuang WL, Yu ML. 2009. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 50:712-718.
13. De Coreaga B. 2006. Predictive factors for response to treatment of chronic hepatitis C. Annals of Hepatology 5:24-28.
14. Decock S, Verslype C, Fevery J. 2007. Hepatitis C and insulin resistance: Mutual interactions. A review. Acta Clin Belg 62:111-119.
15. Di Marco V, Covolo L, Calvaruso V, Levrero M, Puoti M, Suter F, Gaeta GB, Ferrari C, Raimondo G, Fattovich G, Santantonio T, Alberti A, Bruno R, Mussini C, Mondelli M, Donato F, Craxi A. 2013. Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. J Viral Hepat 20:790-800.
16. El-Zayadi A, Selim O, Hamdy H, El-Tawil A, Badran HM, Attia M, Saeed A. 2004. Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients. World J Gastroenterol 10:2963-2966.
17. El Raziky, Attia M, El D, Akel W, Shaker O, Khatab H, Abdo S, Elsharkawy A, Esmat G. 2013. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment. Arab J Gastroenterol 14:94-98.
18. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero- Gomez M. 2011. Meta-analysis: Insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 34:297-305.
19. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:1335- 1374.
21. Ginaldi L, Loreto MF, Corsi MP, Modesti M, De Martinis M. 2001. Immunosenescence and infectious diseases. Microbes Infect 3:851-857.
22. Grasso A, Malfatti F, De Leo P, Martines H, Fabris P, Toscanini F, Anselmo M, Menardo G. 2009. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 51:984-990.
23. Harrison SA. 2006. Correlation between insulin resistance and hepatitis C viral load. Hepatology 43: 1168-1169 1168; author reply.
24. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. 2012. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology 56:464-473.
25. Idrees M, Riazuddin S. 2009. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 9:5.
26. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. 1995. Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699.
27. Ismail MH. 2013. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 20:35-40.
28. Kamal SM, El Kamary, Shardell SS, Hashem MD, Ahmed M, Muhammadi IN, Sayed M, Moustafa K, Hakem A, Ibrahiem SA, Moniem A, Mansour M, Abdelaziz H. 2007. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 46:1732-1740.
29. Kau A, Vermehren J, Sarrazin C. 2008. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 49:634-651.
30. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. 2010. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 105:1970-1977.
31. Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, Hotta H, Maekawa Y, Hayashi Y, Kudo M. 2011. Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load. Digestion 84:5-9.
32. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int 29:74-81.
33. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Haussinger D, Smith CI, Lin A, Pappas SC. 2002. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 37:500-506.
34. McCullough AJ. 2003. Obesity and its nurturing effect on hepatitis C. Hepatology 38:557-559.
35. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361:580-593.
36. Merchante N, de los Santos-Gil, Merino I, Gonzalez-Serrano D, Mira M, Sanz-Sanz JA, Fernandez-Fuertes J, Ruiz-Morales E, del Valle J, Macias J, Moro J, Pineda A. 2009. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J Hepatol 50:684-692.
37. Miyajima I, Kawaguchi T, Fukami A, Nagao Y, Adachi H, Sasaki S, Imaizumi T, Sata M. 2013. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: A population-based study in an HCV hyperendemic area. J Gastroenterol 48:93-100.
38. Monto A. 2002. Hepatitis C and steatosis. Semin Gastrointest Dis 13:40-46.
39. Mukaiya M, Nishi M, Miyake H, Hirata K. 1998. Chronic liver diseases for the risk of hepatocellular carcinoma: A case-control study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases. Hepatogastroenterology 45:2328-2332.
40. Negro F. 2006. Insulin resistance and HCV: Will new knowledge modify clinical management. J Hepatol 45:514-519.
41. Ouzan D, Khiri H, Penaranda G, Joly H, Halfon P. 2005. Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naive genotype 1 patients. Comp Hepatol 4:9.
42. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P. 2001. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34:738-744.
43. Parise ER, Oliveira AC. 2007. [Insulin resistance in chronic hepatitits C]. Arq Gastroenterol 44:178-184.
44. Peres DP, Cheinquer H, Wolf FH, Cheinquer N, Falavigna M, Peres LD. 2013. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients. Ann Hepatol 12:871-875.
45. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, Valla DC. 2003. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 23:45-53.
46. Petta S, Camma C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxi A. 2008. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 103:1136-1144.
47. Qureshi S, Batool U, Iqbal M, Burki UF, Khan NU. 2011. Pre-treatment predictors of response for assessing outcomes to standard treatment in infection with HCV genotype 3. J Coll Physicians Surg Pak 21:64-68.
48. Romero-Gomez M, Del Mar Viloria, Andrade M, Salmeron RJ, Diago J, Fernandez-Rodriguez M, Corpas CM, Cruz R, Grande M, Vazquez L, Munoz-De-Rueda L, Lopez-Serrano P, Gila P, Gutierrez A, Perez ML, Ruiz-Extremera C, Suarez A, Castillo E. 2005. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636-641.
49. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. 2007. Hepatitis C, metabolic syndrome, and inflammatory markers: Results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract 75:320-326.
50. Shaker OG, Eskander EF, Yahya SM, Mohamed MS, Abd-Rabou AA. 2011. Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients. Clin Chim Acta 412:593-598.
51. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104.
52. Suzuki N, Takahashi C. 2007. [Effect of social context on middle-way judgments among the Japanese]. Shinrigaku Kenkyu 77:528-533.
53. Svegliati-Baroni G, Bugianesi E, Bouserhal T, Marini F, Ridolfi F, Tarsetti F, Ancarani F, Petrelli E, Peruzzi E, Lo Cascio, Rizzetto M, Marchesini M, Benedetti G. 2007. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 56:1296-1301.
54. Tarantino G, Conca P, Sorrentino P, Ariello M. 2006. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 21:1266-1268.
55. Tsoulfas G, Goulis I, Giakoustidis D, Akriviadis E, Agorastou P, Imvrios G, Papanikolaou V. 2009. Hepatitis C and liver transplantation. Hippokratia 13:211-215.
56. Vachon ML, Factor SH, Branch AD, Fiel MI, Rodriguez-Torres M, Brau N, Sterling RK, Slim J, Talal AH, Dieterich DT, Sulkowski MS. 2011. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol 54:41-47.
57. Watanabe K, Eto K, Furuno K, Mori T, Kawasaki H, Gomita Y. 1995. Effect of cigarette smoke on lipid peroxidation and liver function tests in rats. Acta Med Okayama 49:271-274.
58. .World Health Organization. Updated July 2013. Hepatitis C. Available from: http://wwwwhoint/mediacentre/factsheets/fs164/en/ Fact sheet N°164.
59. Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, Coate B, DeMasi R, Picchio G, Witek J. 2013. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology 58:1897-1906.
60. Ziada DH, El Saadany, Enaba S, Ghazy M, Hasan M. 2012. The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C. Can J Gastroenterol 26:325-329.